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ways be kept in mind, and that this might 
mimic other disease conditions. Broad dif-
ferential diagnosis and an extended diag-
nostic workup help in establishing the cor-
rect diagnosis. 
 Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Immunomodulation employing a new 
class of biologic agents is increasingly be-
ing used for an expanding array of mostly 
chronic inflammatory autoimmune dis-
eases. The biologic agents allegedly repre-
sent efficacious and relatively safe thera-
peutic agents. Nevertheless, the tumor ne-
crosis factor-  (TNF  )-blocking agents 
have been connected with reactivation of a 
variety of infectious agents, such as myco-
bacterium species and viruses. In these 
cases, the clinical presentation and course 
of infection frequently are atypical. Diag-
nosis may therefore be delayed and needs 
additional steps in the work-up.  Infections 
on TNF  antagonist therapy concern ap-
proximately one-third of etanercept-treat-
ed patients  [1] , including reactivation of 
tuberculosis as the most important, but 
uncommon problem  [2] .
 We report a case of disseminated vari-
cella zoster virus (VZV) infection clini-
cally mimicking vasculitis in a patient on 
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 Abstract 
 Tumor necrosis factor-  (TNF  )-blocking 
agents are immunomodulating agents in-
troduced for treatment of a variety of chron-
ic inflammatory disease conditions. Adverse 
effects include an increased incidence of
infections. Clinically, these infections often 
have atypical presentations that may ham-
per prompt diagnosis. In our report of a pa-
tient on etanercept therapy for rheumatoid 
arthritis, the correct diagnosis was delayed 
because disseminated herpes zoster was 
clinically mimicking vasculitis. Initially as-
suming rheumatoid vasculitis, immunosup-
pression was increased, resulting in wors-
ening of skin lesions. Only an extended 
work-up, including a skin biopsy and viral 
cultures, established the correct diagnosis. 
Management of varicella zoster virus (VZV) 
infection primarily focuses on early initia-
tion of antiviral therapy to control VZV repli-
cation. Therapy with intravenous acyclovir 
followed by oral valacyclovir allowed com-
plete resolution of acute skin changes. In im-
munosuppressed patients, the possibility of 
infection with atypical presentation must al-
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TNF  antagonist treatment with etaner-
cept for rheumatoid arthritis (RA). As-
suming rheumatoid vasculitis, immuno-
suppression was initially increased with 
worsening. Only an extended work-up, in-
cluding a skin biopsy and viral cultures, 
established the correct diagnosis and ther-
apy. 
 Case Report 
 A 70-year-old woman presented with 
multiple, partially confluent hemorrhagic 
bullous lesions with central necrotic areas 
on her left ankle, right leg, right axilla and 
left ear ( fig. 1 ). Her medical history includ-
ed RA with Raynaud’s syndrome, known 
for 3 years. Treatment with etanercept was 
initiated for RA 10 months before admis-
sion. Her medical history included osteo-
penia, arterial hypertension, chronic alco-
holism and smoking.
 Four months before admission, soli-
tary bullous lesions showed up on her dor-
sal left foot. The clinical differential diag-
nosis included fixed drug eruptions, au-
toimmune bullous disease and vasculitic 
lesions. Under the first assumption of
a drug-related reaction, etanercept was 
withheld for 1 month. Nonetheless, the 
number of lesions increased and extended 
to the right leg, the right axilla and the left 
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ear. On account of the clinical presenta-
tion and course in association with RA, 
the diagnosis of rheumatoid vasculitis was 
made. Therapy was modified to include 
corticosteroids at 15 mg prednisolone q.d. 
and methotrexate at 25 mg s.c. once week-
ly in addition to etanercept. On this thera-
py there was further progression of skin 
lesions over the following 4 weeks. Other 
reported symptoms included general mal-
aise, night sweats and fatigue.
 The patient presented to our depart-
ment for a dermatological assessment with 
clinically suspected rheumatoid vasculitis. 
A lesional biopsy was performed, and his-
tology demonstrated an intact intra-epi-
dermal vesicle containing groups of kera-
tinocytes showing ballooning degenera-
tion, and distinct, pale, ground-glass 
nuclear inclusions. Multinucleated epithe-
lial cells were also present in the vesicle. 
The underlying dermis showed a scarce 
perivascular inflammatory infiltration 
and some hemorrhage ( fig. 2 ). These find-
ings were consistent with virotropic chang-
es. On virological culture of a swab, VZV 
was identified. A diagnosis of disseminat-
ed VZV infection due to reactivation was 
made. The patient had experienced four 
episodes of VZV reactivation in the past, 
but these VZV reactivations were strictly 
segmental at the time. Treatment was 
started with intravenous acyclovir 500 mg 
three times daily on 4 consecutive days, 
followed by oral valacyclovir 1 g three 
times daily for another 10 days. At regular 
follow-up examinations, careful debride-
ment of larger lesions was performed and 
wound care with topical steroids was de-
livered. Finally, at 6 months all lesions 
were healed with residual hyperpigmenta-
tion and dysesthesia. A neurologist diag-
nosed post-herpetic neuralgia, but this 
was mild and did not necessitate further 
analgesic therapy.
 Discussion 
 RA is a chronic inflammatory disease 
with extra-articular manifestations. Der-
matologic manifestations include rheu-
matoid nodules, pyoderma gangrenosum, 
granulomatous dermatitis, rheumatoid 
neutrophilic dermatitis, and rheumatoid 
vasculitis. Rheumatoid vasculitis has an 
overall annual incidence of less than 1% 
 [3] . Clinically, rheumatoid vasculitis pre-
a b
 Fig. 1. Clinical findings in an immuno-
compromised patient with VZV reactiva-
tion. Scattered hemorrhagic lesions with 
necrotic areas and erythematous sur-
rounding are seen. 
 Fig. 2.  a Scanning magnification of an intact intra-epidermal vesicle in which the residual keratinocytes show 
intracellular edema (ballooning degeneration) and acantholysis.  b Detailed view of acantholytic keratinocytes 
with intranuclear inclusions, characteristic for herpetic viral changes. 
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sents with painless or tender, reddish to 
brown lesions, typically located on distal 
and in particular lower extremities. Also 
bullous lesions like hemorrhagic blisters 
can be found in rheumatoid vasculitis  [4] . 
 Cutaneous adverse effects of a TNF  -
blocking agent therapy include infections, 
dermatitis, and drug-related eruptions, 
less commonly vasculitis, psoriasis-like 
eruptions, drug-induced systemic lupus 
erythematosus, dermatomyositis, lym-
phomatoid papulosis-like eruptions, and 
intravascular histiocytosis  [5, 6] .
 In our case, rheumatoid vasculitis was 
suspected on the base of the clinical pre-
sentation with symmetrically distributed, 
hemorrhagic and necrotic lesions of the 
lower extremities and further progression 
after brief interruption of etanercept ther-
apy. For this reason, etanercept treatment 
was reintroduced, in combination with 
systemic corticosteroids and methotrex-
ate. The cutaneous lesions worsened, and 
a biopsy was performed. Histology re-
vealed virotropic epidermal changes, and 
virus culture identified VZV.
 The development and reactivation of 
viral infections is well documented on 
TNF  -antagonist therapy  [7] . In a report 
in 2007, the authors identified reactivation 
of VZV in 3% of patients on TNF  antago-
nists (infliximab, adalimumab, etaner-
cept) prescribed for chronic inflammatory 
disease  [8] . In contrast to infliximab and 
adalimumab, etanercept did not signifi-
cantly increase the risk of herpes zoster
 [9] . VZV reactivations tend to be more 
complicated in immunocompromised pa-
tients. The incidence in the Wegener’s 
Granulomatosis Etanercept Trial (WGET) 
cohort was 45 cases per 1,000 patient-years 
 [10] . These patients often showed dissemi-
nated infection with vesicles and other vi-
remia-related skin manifestations at a dis-
tance from the affected dermatome. Simi-
lar to our case, atypical recurrent varicella 
was described in a 2008 report  [11] . Prompt 
antiviral therapy is important to reduce 
the incidence of acute complications and 
long-term sequelae. Immunosuppressed 
individuals and patients over the age of 50 
have a greater risk of developing posther-
petic neuralgia  [12] . First-line treatment of 
VZV infection or reactivation is systemic 
antiviral therapy. Management primarily 
focuses on early antiviral therapy and suf-
ficient analgesic treatment  [13] started 
within 1 week of onset of VZV symptoms 
or any time before full crusting of lesions 
 [12] . In clinical practice, brivudin, famci-
clovir and valacyclovir have better compli-
ance than acyclovir: oral acyclovir requires 
dosing every 5 h. Brivudin shows the low-
est inhibiting concentration for VZV of all 
these drugs and needs once daily dosing 
only. However, in Switzerland, brivudin is 
not registered for use in immunosup-
pressed patients. Furthermore, brivudin
is contraindicated in conjunction with 5-
fluorouracil (5-FU) because of cumula-
tive 5-FU toxicity due to irreversible inhi-
bition of 5-FU catabolism induced by bri-
vudin  [14] .
 In conclusion, we present a case of 
atypical presentation of disseminated 
VZV infection clinically mimicking vas-
culitis in a patient with RA on the TNF  -
blocking agent etanercept. Not until an ex-
tended work-up, including skin biopsy and 
viral cultures, were performed was the 
correct diagnosis established. In immuno-
suppressed patients, including those on 
the newer TNF  inhibitors, the possibility 
of infection with atypical presentation 
must always be kept in mind, and that this 
might mimic other conditions. Only clini-
cal suspicion and appropriate diagnostic 
procedures will promptly enable correct 
diagnosis and management  [15] .
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